Etrumadenant

Etrumadenant (AB928) is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. Etrumadenant relieves adenosine-mediated immune suppression. Etrumadenant has immunomodulatory and antitumor activities[1][2].

Product Specifications

CAS Number

[2239273-34-6]

Product Name Alternative

AB928

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Adenosine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/etrumadenant.html

Purity

99.67

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

N#CC1=CC=CC(C2=NC(N)=NC(C3=CN(CC4=NC(C(C)(O)C)=CC=C4)N=N3)=C2)=C1C

Molecular Formula

C23H22N8O

Molecular Weight

426.47

Precautions

H315, H319, H320

References & Citations

[1]Seitz L, et al. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Invest New Drugs. 2019 Aug;37 (4) :711-721.|[2]Daniel DiRenzo, et al. AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression [abstract].